The last time we checked on reports about AstraZeneca’s COVID-19 vaccine, the pharmaceutical firm had admitted that its product could cause a deadly side effect from blood clotting. The stunning admission came during a court proceedingSince the vaccine was approved in Britain in December 2020, over three billion doses have been supplied globally.
…Sheena Cruickshank, an immunologist at the University of Manchester, said the company’s decision to pull the shot was “not a surprise.” Unlike other manufacturers, AstraZeneca did not update its shot to target emerging virus variants because it used a vaccine technology, known as a viral vector, that was less amenable to such changes.
Partial results from its first major trial — which Britain used to authorize the vaccine — were clouded by a manufacturing mistake that researchers didn’t immediately acknowledge. Insufficient data about how well the vaccine protected older people led some countries to initially restrict its use to younger populations before reversing course.technology as Pfizer.
AstraZeneca Plc Chief Executive Officer Pascal Soriot envisions his company bringing more affordable drugs to people who need to lose a modest amount of weight for health reasons but don’t necessarily have obesity.